These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 25986996)
21. Bevacizumab as Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Literature Review. Kini SD; Yiu DW; Weisberg RA; Davila JF; Chelius DC Ann Otol Rhinol Laryngol; 2019 May; 128(5):467-471. PubMed ID: 30693788 [TBL] [Abstract][Full Text] [Related]
22. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial. Riss D; Burian M; Wolf A; Kranebitter V; Kaider A; Arnoldner C Head Neck; 2015 Jun; 37(6):783-7. PubMed ID: 24595923 [TBL] [Abstract][Full Text] [Related]
23. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy. Karnezis TT; Davidson TM Laryngoscope; 2012 Mar; 122(3):495-7. PubMed ID: 22147664 [TBL] [Abstract][Full Text] [Related]
32. The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review. Harrison L; Kundra A; Jervis P J Laryngol Otol; 2018 Oct; 132(10):866-871. PubMed ID: 30191780 [TBL] [Abstract][Full Text] [Related]
34. Hereditary haemorrhagic telangiectasia: to transplant or not to transplant - is there a right time for liver transplantation? Muller YD; Oppliger R; Breguet R; Meyer P; Rubbia-Brandt L; Petignat PA; Harr T; Dayer E; Seebach JD Liver Int; 2016 Dec; 36(12):1735-1740. PubMed ID: 27864873 [TBL] [Abstract][Full Text] [Related]
35. Duration of effectiveness of coblation for recurrent epistaxis in hereditary hemorrhagic telangiectasia. Feller CN; Adams JA; Friedland DR; Poetker DM Am J Otolaryngol; 2022; 43(3):103409. PubMed ID: 35216850 [TBL] [Abstract][Full Text] [Related]
36. An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia. Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN Haemophilia; 2020 Nov; 26(6):1038-1045. PubMed ID: 32432841 [TBL] [Abstract][Full Text] [Related]
37. ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia. Dupuis-Girod S; Ambrun A; Decullier E; Samson G; Roux A; Fargeton AE; Rioufol C; Schwiertz V; Disant F; Chapuis F; Donazzolo Y; Paintaud G; Edery P; Faure F MAbs; 2014; 6(3):794-9. PubMed ID: 24481211 [TBL] [Abstract][Full Text] [Related]
38. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study. Geisthoff UW; Seyfert UT; Kübler M; Bieg B; Plinkert PK; König J Thromb Res; 2014 Sep; 134(3):565-71. PubMed ID: 25005464 [TBL] [Abstract][Full Text] [Related]
39. Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia. Penaloza A; Vekemans MC; Lambert C; Hermans C Blood Coagul Fibrinolysis; 2011 Oct; 22(7):616-8. PubMed ID: 21885956 [TBL] [Abstract][Full Text] [Related]
40. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia. Kanellopoulou T; Alexopoulou A Expert Opin Biol Ther; 2013 Sep; 13(9):1315-23. PubMed ID: 23815519 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]